文献速递糖尿病

晚期糖基化终末产物预测2型糖尿病肾功能丧失和高危慢性肾脏病

Advanced Glycation End Products Predict Loss of Renal Function and High-Risk Chronic Kidney Disease in Type 2 Diabetes.
PubMed 文献 · Diabetes Care · 2022-01-01

在ACCORD(n=1150)和VADT(n=447)队列中,由羧甲基赖氨酸、羧乙基赖氨酸及甲基乙二醛、3-脱氧葡糖酮、乙二醛氢咪唑酮计算的复合AGE评分,在校正基线及随访HbA1c和其他危险因素后,与eGFR下降、30%肾功能丧失(RFL)、40%RFL、大量白蛋白尿和高危慢性肾脏病(hrCKD)相关,并改善30%RFL的净重分类和相对整合判别。

要点

  • ACCORD中AGE评分与30%RFL相关(HR 1.42,95%CI 1.13-1.78,P=0.003)。
  • VADT中用ACCORD系数计算的AGE评分与30%RFL相关(HR 1.37,95%CI 1.03-1.82,P=0.03)。
  • AGE评分改善30%RFL的NRI(ACCORD 23%,P=0.02;VADT 24%,P=0.03)。

核心结论

  • 数据进一步支持AGEs在糖尿病肾病中的因果作用,且独立于血糖控制,并提示复合AGE panel在预测长期肾功能下降方面的效用。

研究设计与样本

  • 在ACCORD(n=1,150)和VADT(n=447)参与者中,于基线血清和血浆样本分别测量羧甲基赖氨酸、羧乙基赖氨酸及甲基乙二醛、3-脱氧葡糖酮、乙二醛氢咪唑酮。
  • 由各AGE的z评分计算复合AGE评分;主要结局为eGFR持续下降30%(两个队列均为30%RFL),ACCORD的次要结局为40%RFL、大量白蛋白尿和高危慢性肾脏病(hrCKD)。

主要发现

  • ACCORD中,校正基线及随访HbA1c和其他危险因素后,AGE评分与eGFR下降相关(β估计值-0.66 mL/min·1.73 m²/年;P=0.001)。
  • ACCORD中,AGE评分与30%RFL相关(HR 1.42,95%CI 1.13-1.78;P=0.003),与40%RFL相关(HR 1.40,95%CI 1.13-1.74;P=0.003)。
  • ACCORD中,AGE评分与大量白蛋白尿相关(HR 1.53,95%CI 1.13-2.06;P=0.006),与hrCKD相关(HR 1.88,95%CI 1.37-2.57;P<0.0001)。
  • ACCORD中,AGE评分改善30%RFL的净重分类(NRI 23%;P=0.02)和相对整合判别改善(相对IDI 7%;P=0.009)。
  • VADT中,用ACCORD衍生系数计算的AGE评分与30%RFL相关(HR 1.37,95%CI 1.03-1.82;P=0.03),改善NRI(24%;P=0.03),但未改善IDI(P=0.18)。

临床怎么用

  • 原文结论认为这些数据进一步支持AGEs在糖尿病肾病中的因果作用且独立于血糖控制,并提示复合AGE panel在预测长期肾功能下降方面的效用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the association of a multicomponent advanced glycation end product (AGE) panel with decline in kidney function and its utility in predicting renal function loss (RFL) when added to routine clinical measures in type 2 diabetes. RESEARCH DESIGN AND METHODS: Carboxymethyl and carboxyethyl lysine and methylglyoxal, 3-deoxyglucosone, and glyoxal hydroimidazolones were measured in baseline serum and plasma samples, respectively, from Action to Control Cardiovascular Risk in Diabetes (ACCORD) (n = 1,150) and Veterans Affairs Diabetes Trial (VADT) (n = 447) participants. A composite AGE score was calculated from individual AGE z scores. The primary outcome was a sustained 30% decline in estimated glomerular filtration rate (eGFR) (30% RFL in both cohorts). Secondary outcomes (in ACCORD) were 40% RFL, macroalbuminuria, and high-risk chronic kidney disease (hrCKD). RESULTS: After adjustment for baseline and follow-up HbA1c and other risk factors in ACCORD, the AGE score was associated with reduction in eGFR (β-estimate -0.66 mL/min ⋅ 1.73 m2 per year; P = 0.001), 30% RFL (hazard ratio 1.42 [95% CI 1.13-1.78]; P = 0.003), 40% RFL (1.40 [1.13-1.74]; P = 0.003), macroalbuminuria (1.53 [1.13-2.06]; P = 0.006), and hrCKD (1.88 [1.37-2.57]; P < 0.0001). AGE score improved net reclassification (NRI) and relative integrated discrimination (IDI) for 30% RFL (NRI 23%; P = 0.02) (relative IDI 7%; P = 0.009). In VADT, the AGE score calculated by the ACCORD-derived coefficients was associated with 30% RFL (1.37 [1.03-1.82); P = 0.03) and improved NRI (24%; P = 0.03) but not IDI (P = 0.18). CONCLUSIONS: These data provide further support for a causal role of AGEs in diabetic nephropathy independently of glycemic control and suggest utility of the composite AGE panel in predicting long-term decline in renal function.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Koska J, Gerstein HC, Beisswenger PJ, et al. Advanced Glycation End Products Predict Loss of Renal Function and High-Risk Chronic Kidney Disease in Type 2 Diabetes. Diabetes Care. 2022. PMID: 35051276. doi:10.2337/dc21-2196

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。